Korea's Hanmi Pharmaceutical to launch first homegrown GLP-1 drug Eppe by year-end, potentially undercutting Wegovy and Mounjaro with estimated ₩150,000 ($111) per four-week supply.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Iraq's state tanker company arranges VLCC to transport 2 million barrels of crude beyond Strait of Hormuz, shifting oil strategy to offer oil outside Persian Gulf
-
2
Al Jazeera: Russia faces €18.7 billion nuclear plant decommissioning funding gap
-
3
Needham: Meta Valuation Rises 35% After Including $628 Billion in Off-Balance Sheet Liabilities
-
4
a16z Podcast: AI-Native Startups Are Challenging Traditional Giants in Enterprise Software Through "End-to-End Processes"
-
5
Stellar (XLM) accounts for 37% of the global RWA tokenization market, with daily inflows of $36.4 million.
-
6
Coinbase CEO Brian Armstrong: AI agents may eventually surpass humans in trading volume, and existing payment systems are not suited for their needs.
-
7
Ripple is heavily promoting XRP in college sports through multiple partnerships, including prominent advertisements at the University of Kansas football stadium.
-
8
Books Become Precious Property in Gaza Conflict, Repair Material Prices Soar
-
9
Musk reposted a tweet stating that Starlink can stream 5 college football games simultaneously on commercial flights.
-
10
George Long, founder of LIM Advisors: The company has been established for 30 years, and holds a cautiously optimistic view on Asian markets, precious metals, and Chinese equities.
Markets Today
Recommended Reading


